Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.

Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.

Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.

Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.

A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.

While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.